Publications
-
Clinical risk factors for primary graft dysfunction after lung transplantation.
Diamond JM,
Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, Lederer DJ, Cantu E, Kohl BA, Lama VN, Bhorade SM, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Shah AS, Weinacker A, Arcasoy S, Shah PD, Wilkes DS, Ware LB, Palmer SM, Christie JD.
Am J Respir Crit Care Med.
2013;
187
(5):
527-34
-
Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.
Shah RJ,
Diamond JM, Cantu E, Lee JC, Lederer DJ, Lama VN, Orens J, Weinacker A, Wilkes DS, Bhorade S, Wille KM, Ware LB, Palmer SM, Crespo M, Localio AR, Demissie EJ, Kawut SM, Bellamy SL, Christie JD.
Chest.
2013
-
Still a man's world, but why?
Weinacker A,
Stapleton RD.
Crit Care.
2013;
17
(1):
113
-
A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.
Shah RJ,
Bellamy SL, Localio AR, Wickersham N, Diamond JM, Weinacker A, Lama VN, Bhorade S, Belperio JA, Crespo M, Demissie E, Kawut SM, Wille KM, Lederer DJ, Lee JC, Palmer SM, Orens J, Reynolds J, Shah A, Wilkes DS, Ware LB, Christie JD.
J Heart Lung Transplant.
2012;
31
(9):
942-9
-
Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.
Diamond JM,
Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Bhorade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Arcasoy S, Wilkes DS, Ware LB, Christie JD.
PLoS One.
2012;
7
(12):
e51932
-
High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study.
Pickham D,
Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, Liu JN, Drew BJ.
Crit Care Med.
2012;
40
(2):
394-9
-
Variation in PTX3 is associated with primary graft dysfunction after lung transplantation.
Diamond JM,
Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Weill D, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer SM, Christie JD.
Am J Respir Crit Care Med.
2012;
186
(6):
546-52
-
Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis.
Sims MW,
Beers MF, Ahya VN, Kawut SM, Sims KD, Lederer DJ, Palmer SM, Wille K, Lama VN, Shah PD, Orens JB, Bhorade S, Crespo M, Weinacker A, Demissie E, Bellamy S, Christie JD, Ware LB.
Chest.
2011;
140
(2):
489-96
-
Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction.
Diamond JM,
Kawut SM, Lederer DJ, Ahya VN, Kohl B, Sonett J, Palmer SM, Crespo M, Wille K, Lama VN, Shah PD, Orens J, Bhorade S, Weinacker A, Demissie E, Bellamy S, Christie JD, Ware LB.
Am J Transplant.
2011;
11
(3):
561-7
-
Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.
Diamond JM,
Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Kohl BA, Deutschman CC, Arcasoy S, Shah AS, Belperio JA, Wilkes D, Reynolds JM, Ware LB, Christie JD.
Am J Transplant.
2011;
11
(11):
2517-22
-
Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis.
Fang A,
Studer S, Kawut SM, Ahya VN, Lee J, Wille K, Lama V, Ware L, Orens J, Weinacker A, Palmer SM, Crespo M, Lederer DJ, Deutschman CS, Kohl BA, Bellamy S, Demissie E, Christie JD.
Chest.
2011;
139
(4):
782-7
-
Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study.
Lederer DJ,
Kawut SM, Wickersham N, Winterbottom C, Bhorade S, Palmer SM, Lee J, Diamond JM, Wille KM, Weinacker A, Lama VN, Crespo M, Orens JB, Sonett JR, Arcasoy SM, Ware LB, Christie JD.
Am J Respir Crit Care Med.
2011;
184
(9):
1055-61
-
The "slow code" should be a "no code".
Weinacker A,
Am J Bioeth.
2011;
11
(11):
27-9
-
Construct validity of the definition of primary graft dysfunction after lung transplantation.
Christie JD,
Bellamy S, Ware LB, Lederer D, Hadjiliadis D, Lee J, Robinson N, Localio AR, Wille K, Lama V, Palmer S, Orens J, Weinacker A, Crespo M, Demissie E, Kimmel SE, Kawut SM.
J Heart Lung Transplant.
2010;
29
(11):
1231-9
-
Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation.
Hoffman SA,
Wang L, Shah CV, Ahya VN, Pochettino A, Olthoff K, Shaked A, Wille K, Lama VN, Milstone A, Ware LB, Orens J, Weinacker A, Demissie E, Bellamy S, Kawut SM, Hancock WW, Christie JD.
Am J Transplant.
2009;
9
(2):
389-96
-
Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.
Christie JD,
Shah CV, Kawut SM, Mangalmurti N, Lederer DJ, Sonett JR, Ahya VN, Palmer SM, Wille K, Lama V, Shah PD, Shah A, Weinacker A, Deutschman CS, Kohl BA, Demissie E, Bellamy S, Ware LB.
Am J Respir Crit Care Med.
2009;
180
(10):
1010-5
-
Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation.
Kawut SM,
Okun J, Shimbo D, Lederer DJ, De Andrade J, Lama V, Shah A, Milstone A, Ware LB, Weinacker A, Demissie E, Christie JD.
Chest.
2009;
136
(1):
237-44
-
Randomized clinical trial of activated protein C for the treatment of acute lung injury.
Liu KD,
Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Phillips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA.
Am J Respir Crit Care Med.
2008;
178
(6):
618-23
-
Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.
Christie JD,
Robinson N, Ware LB, Plotnick M, De Andrade J, Lama V, Milstone A, Orens J, Weinacker A, Demissie E, Bellamy S, Kawut SM.
Am J Respir Crit Care Med.
2007;
175
(1):
69-74
-
Management strategies for patients with pulmonary hypertension in the intensive care unit.
Zamanian RT,
Haddad F, Doyle RL, Weinacker AB.
Crit Care Med.
2007;
35
(9):
2037-50
-
Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.
Covarrubias M,
Ware LB, Kawut SM, De Andrade J, Milstone A, Weinacker A, Orens J, Lama V, Wille K, Bellamy S, Shah C, Demissie E, Christie JD.
Am J Transplant.
2007;
7
(11):
2573-8
-
High dose cyclophosphamide efficacy in a patient with refractory anti-MuSK positive myasthenia gravis
Lin P,
Martin B, Weinacker A, So Y.
Muscle & Nerve.
2006:
33
433-435
-
Smoking in movies.
Glantz SA,
Polansky J.
Chest.
2006;
129
(2):
495; author reply 495-6
-
Lung transplantation: A decade of experience
Moffatt SD,
Demers P, Robbins RC, Doyle R, Weinacker A, Henig N, Theodore J, Reitz BA, Whyte RI.
J Heart Lung Transplant.
2005:
24
145-151
-
Smoking in contemporary American cinema.
Omidvari K,
Lessnau K, Kim J, Mercante D, Weinacker A, Mason C.
Chest.
2005;
128
(2):
746-54
-
The value of preoperative pulmonary rehabilitation.
Takaoka ST,
Weinacker AB.
Thorac Surg Clin.
2005;
15
(2):
203-11
-
Intensive care unit support of hematopoietic stem cell transplant recipients: a case for cautious optimism.
Weinacker A,
Crit Care Med.
2003;
31
(6):
1873-5
-
Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia.
Fowler RA,
Flavin KE, Barr J, Weinacker AB, Parsonnet J, Gould MK.
Chest.
2003;
123
(3):
835-44
-
Blood cultures in the critical care unit: improving utilization and yield.
Shafazand S,
Weinacker AB.
Chest.
2002;
122
(5):
1727-36
-
Ethical issues in the long-term management of progressive degenerative neuromuscular diseases.
Vaszar LT,
Weinacker AB, Henig NR, Raffin TA.
Semin Respir Crit Care Med.
2002;
23
(3):
307-14
-
Nodular invasive tracheobronchitis due to Aspergillus in a patient with systemic lupus erythematosus.
Angelotti T,
Krishna G, Scott J, Berry G, Weinacker A.
Lupus.
2002;
11
(5):
325-8
-
A cystic upper lobe lesion in a healthy nonsmoking man.
Leonard CT,
Weinacker A, Berry G, Whyte RI.
Chest.
2001;
120
(5):
1725-7
-
Acute respiratory distress syndrome: physiology and new management strategies.
Weinacker AB,
Vaszar LT.
Annu Rev Med.
2001:
52
221-37
-
Diagnostic yield of screening colonoscopies in lung transplant candidates.
Singer LG,
Weinacker AB, Levin L, Doyle RL, Theodore J.
Transplantation.
2001;
72
(3):
530-2
-
A brave new world: remote intensive care unit for the 21st century.
Shafazand S,
Shigemitsu H, Weinacker AB.
Crit Care Med.
2000;
28
(12):
3945-6
-
The patient's response to medical futility.
McGee DC,
Weinacker AB, Raffin TA.
Arch Intern Med.
2000;
160
(11):
1565-6
-
Withdrawing life support from the critically ill.
McGee DC,
Weinacker AB, Raffin TA.
Chest.
2000;
118
(5):
1238-9
-
Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma.
Tafreshi MJ,
Weinacker AB.
Pharmacotherapy.
1999;
19
(8):
974-8
-
Inhalational anthrax: epidemiology, diagnosis, and management.
Shafazand S,
Doyle R, Ruoss S, Weinacker A, Raffin TA.
Chest.
1999;
116
(5):
1369-76
-
Quality of life and lung volume reduction surgery.
Faul JL,
Doyle RL, Weinacker AB, Raffin TA.
Am J Crit Care.
1999;
8
(6):
359-60
-
Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma.
Schwarzenberger P,
Lei D, Freeman SM, Ye P, Weinacker A, Theodossiou C, Summer W, Kolls JK.
Am J Respir Cell Mol Biol.
1998;
19
(2):
333-7
-
Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana.
Schwarzenberger P,
Harrison L, Weinacker A, Gaumer R, Theodossiou C, Summer W, Ye P, Marrogi AJ, Ramesh R, Freeman S, Kolls J.
J La State Med Soc.
1998;
150
(4):
168-74
-
Systematic reviews and evidence-based critical care medicine: a step in the right direction.
Gould MK,
Leonard CT, Weinacker AB, Raffin TA.
Am J Med.
1998;
105
(6):
551-3
-
The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study.
Schwarzenberger P,
Harrison L, Weinacker A, Marrogi A, Byrne P, Ramesh R, Theodossiou C, Gaumer R, Summer W, Freeman SM, Kolls JK.
Hum Gene Ther.
1998;
9
(17):
2641-9
-
Distribution of integrins alpha v beta 6 and alpha 9 beta 1 and their known ligands, fibronectin and tenascin, in human airways.
Weinacker A,
Ferrando R, Elliott M, Hogg J, Balmes J, Sheppard D.
Am J Respir Cell Mol Biol.
1995;
12
(5):
547-56
-
Effects of beta subunit cytoplasmic domain deletions on the recruitment of the integrin alpha v beta 6 to focal contacts.
Cone RI,
Weinacker A, Chen A, Sheppard D.
Cell Adhes Commun.
1994;
2
(2):
101-13
-
Idiopathic giant bullous emphysema (vanishing lung syndrome): imaging findings in nine patients.
Stern EJ,
Webb WR, Weinacker A, Müller NL.
AJR Am J Roentgenol.
1994;
162
(2):
279-82
-
Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor.
Weinacker A,
Chen A, Agrez M, Cone RI, Nishimura S, Wayner E, Pytela R, Sheppard D.
J Biol Chem.
1994;
269
(9):
6940-8
-
Upper and middle lobe bronchoalveolar lavage to diagnose Pneumocystis carinii pneumonia.
Yung RC,
Weinacker AB, Steiger DJ, Miller TR, Stern EJ, Salmon CJ, Chernoff DN, Luistro MG, Kuntz S, Golden JA.
Am Rev Respir Dis.
1993;
148
(6 Pt 1):
1563-6
Help